X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216807
https://www.ema.europa.eu/en/documents/overview/mycapssa-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-16-2022-42781.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-institutional-llc-viatris-company-issues-voluntary-recall-one-lot-octreotide-acetate-injection
https://news.bloomberglaw.com/health-law-and-business/mylan-recalls-lot-of-octreotide-acetate-injection-500-mcg-ml?context=search&index=20
https://www.globenewswire.com/news-release/2022/09/16/2517587/0/en/CHMP-adopts-positive-opinion-for-Mycapssa-for-the-treatment-of-Acromegaly.html
https://www.globenewswire.com/news-release/2022/09/07/2511277/0/en/Amryt-to-Present-Data-from-MPOWERED-Phase-3-Trial-of-Mycapssa-oral-octreotide-at-ENEA-2022.html
https://www.globenewswire.com/news-release/2022/07/14/2479558/0/en/Amryt-Receives-Orphan-Drug-Designation-from-the-FDA-for-Mycapssa-oral-octreotide-for-the-Treatment-of-Carcinoid-Syndrome.html
https://www.globenewswire.com/news-release/2022/06/08/2458549/0/en/Amryt-to-Present-Data-from-OPTIMAL-and-MPOWERED-Phase-3-Trials-Open-Label-Extension-of-Mycapssa-oral-octreotide-at-ENDO-2022.html
https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables
https://www.globenewswire.com/news-release/2022/04/13/2421761/0/en/Amryt-Announces-Positive-Long-Term-Safety-and-Efficacy-Data-for-Mycapssa-oral-octreotide-from-the-2nd-Year-of-OPTIMAL-Open-Label-Extension-Study-in-Acromegaly-Patients.html
https://www.globenewswire.com/news-release/2022/01/11/2364667/0/en/Amryt-Announces-Positive-Long-Term-Safety-and-Efficacy-Data-confirming-the-role-for-Mycapssa-oral-octreotide-in-the-management-of-Acromegaly-patients-who-have-responded-to-and-tole.html
https://trialsitenews.com/results-from-amyrt-pharmas-phase-3-mpowered-trial-of-mycapssa-oral-octreotide-for-acromegaly-published-in-the-lancet-diabetes-endocrinology/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-25-2021-1629867988.pdf
https://endpts.com/a-biotech-with-a-yen-for-pricey-rare-disease-drugs-and-bargain-basement-shopping-adopts-another-orphan-in-latest-ma-pact/
https://ir.chiasma.com/news-releases/news-release-details/chiasma-announces-positive-topline-results-mpoweredtm-phase-3
https://www.biospace.com/article/chiasma-s-octreotide-capsules-could-be-answer-to-acromegaly-patients-treatment-burdens/
https://www.globenewswire.com/news-release/2020/08/31/2086104/0/en/Chiasma-Announces-U-S-Commercial-Launch-and-Availability-of-MYCAPSSA-the-First-and-Only-Oral-Somatostatin-Analog-for-Patients-with-Acromegaly.html
https://www.globenewswire.com/news-release/2020/07/27/2068179/0/en/Chiasma-Announces-48-Week-Safety-and-Efficacy-Data-from-the-Open-Label-Extension-Study-of-its-CHIASMA-OPTIMAL-Phase-3-Trial-Evaluating-MYCAPSSA-in-Patients-with-Acromegaly.html
https://www.prnewswire.com/news-releases/camargo-client-chiasma-receives-fda-approval-for-first-and-only-oral-somatostatin-analog-for-long-term-maintenance-treatment-of-acromegaly-301087700.html
https://www.globenewswire.com/news-release/2020/06/26/2054210/0/en/Chiasma-Announces-FDA-Approval-of-MYCAPSSA-Octreotide-Capsules-the-First-and-Only-Oral-Somatostatin-Analog.html
https://www.fiercepharma.com/pharma/thanks-to-complex-manufacturing-novartis-expects-blockbuster-sandostatin-lar-to-steer-clear
https://www.in-pharmatechnologist.com/Article/2020/02/03/Novartis-expects-slow-erosion-by-Sandostatin-generics
https://www.fiercepharma.com/pharma/novartis-offloads-lagging-endocrine-drugs-pipeline-followup-to-recordati-for-390m?utm_source=internal&utm_medium=rss
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204669
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203765
https://www.fiercepharma.com/marketing/novartis-app-to-support-net-cancer-community-gets-apple-featured-boost
http://www.pharmatimes.com/news/glide_raises_3.2m_for_solid_dose_injector_programme_1185653
http://www.fiercepharma.com/pharma/generics-set-to-undercut-blockbusters-from-merck-novartis-bms-2017
http://www.fiercepharma.com/marketing/fda-promo-police-slap-four-more-pharmas-year-end-enforcement-spree
https://www.pharmacompass.com/pdf/news/us-fda-enforcement-report-1june2016-1464785216.pdf
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/government-restores-customs-duty-exemption-on-three-drugs/articleshow/51028313.cms
http://www.prnewswire.com/news-releases/glide-technologies-announces-successful-proof-of-concept-with-novel-exenatide-solid-dose-formulation-564345691.html
http://www.biospectrumindia.com/biospecindia/features/222801/acromegaly-treatment-oral-octreotide-capture-share-injectables-market-late-2015
http://www.fiercebiotech.com/story/roche-out-door-chiasma-raising-56m-go-it-alone/2015-01-02
Market Place
Share 
